The agreement gives Roche a potential source of small molecule agonists of an undisclosed G-protein coupled receptor.
Genentech is handing over an upfront fee and committing to milestones to apply DiCE’s small molecule platform to targets of interest.
The five-year pact puts CRT in charge of discovering drugs that affect protein assembly and taking them through phase 1.
AMRC will provide preclinical support to startups working out of an incubator overseen by the foundation.
The agreement will see Vernalis turn its fragment and structure-based drug discovery platform on undisclosed cancer targets.
Carmot will use its lead-identification technology to provide Amgen with a stream of prospects against conditions including Parkinson’s disease.
The product of a merger of Pluriomics and Axiogenesis, iPSC company Ncardia has signed licensing deals with Roche and Evotec.
Ultragenyx Pharmaceuticals chalked up another win for its rare bone disease drug, burosumab, keeping it on track for a U.S. regulatory filing.
Enyo Pharma has successfully identified potential targets of its preclinical molecule series EYP002 with Charles River's technology.
HitGen has formed a drug discovery research collaboration with Boehringer Ingelheim to identify novel small-molecule leads.